Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma

American Journal of Surgery

Volumn 177, Issue 5, 1999, Pages 405-410

  Rose, D Michael ^a   Chapman, William C ^a   Brockenbrough, Andrew T ^a   Wright, J Kelly ^a   Rose, Amy T ^a   Meranze, Steven ^a   Mazer, Murray ^a   Blair, Taylor ^a   Blanke, C D ^a   Debelak, J P ^a   Pinson, C Wright ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTERY CATHETERIZATION; ARTICLE; ARTIFICIAL EMBOLISM; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER CELL CARCINOMA; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CATHETERIZATION; CHEMOEMBOLIZATION, THERAPEUTIC; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; HEPATIC ARTERY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NAUSEA; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VOMITING;

EID: 0033136957     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(99)00069-0     Document Type: Article

References (28)

1. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75(suppl 1):171-190.
2. Liu C-L, Fan S-T. Nonresectional therapies for hepatocellular carcinoma. Am J Surg. 1997;173:358-365.
3. Farmer DO, Rosove MH, Shaked A, Busuttil RW. Current treatment modalities for haepatocellular carcinoma. Ann Surg. 1994;219:236-247.
4. Bruix J. Treatment of hepatocellular carcinoma. Hepatology. 1997;25:259-262.
5. Trinchet J-C, Beaugrand M. Treatment of hepatocellular carcinoma in patients with cirrhosis. J Hepatol. 1997;27:756-765.
6. Venook AP. Treatment of hepatocellular carcinoma: too many options? J Clin Oncol. 1994;12:1323-1334.
7. Beahrs OH. Manual for Staging Cancer. Philadelphia: Lippincott; 1988.
8. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J R Stat Soc. 1958;8:423-446.
9. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol. 1990;11:181-184.
10. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. NEJM. 1995;332:1256-1261.
11. Vetter D, Wenger JJ, Bergier JM, et al. Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western comparative study in 60 patients. Hepatology. 1991;13:427-433.
12. Bronowicki JP, Vetter D, Dumas F, et al. Transcatheter oily chemoembolization for hepatocellular carcinoma: a 4-year study of 127 patients. Cancer. 1994;74:16-24.
13. Stefanini GF, Amorati P, Biselli M, et al. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma: an Italian experience. Cancer. 1995;75:2427-2434.
14. Bronowicki J-P, Boudjema K, Chone L, et al. Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma. J Hepatol. 1996;24:293-300.
15. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States: prognostic features, treatment outcome, and survival. Cancer. 1996;77:2217-2222.
16. Marcos-Alvarez A, Jenkins RL, Washburn WK, et al. Multimodality treatment of hepatocellular carcinoma in a hepatobiliary specialty center. Arch Surg. 1996;131:292-298.
17. Ryder SD, Rizzi PM, Metivier E, et al. Chemoembolization with lipiodol and doxorubicin: applicability in British patients with hepatocellular carcinoma. Gut. 1996;38:125-128.
18. Cohen SE, Safadi R, Verstandig A, et al. Liver-spleen infarcts following transcatheter chemoembolization: a case report and review of the literature on adverse effects. Dig Dis Sci. 1997;42:938-943.
19. Bismuth H, Morino M, Sherlock D, et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg. 1992;163:387-394.
20. Berger DH, Carrasco CH, Hohn DC, Curley SA. Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications. J Surg Oncol. 1995;60:116-121.
21. Lopez RR, Pan S, Lois JF, et al. Transarterial chemoembolization is a safe treatment for unresectable hepatic malignancies. Am Surg. 1997;63:923-926.
22. Okuda K, Obata H, Ohtsuki T, et al. Prognosis of primary hepatocellular carcinoma. Hepatology. 1984;4:3S-6S.
23. Farinati F, De Maria N, Marafin C, et al. Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. Dig Dis Sci. 1996;41:2332-2339.
24. Mondazzi L, Bottelli R, Brambilla G, et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology. 1994;19:1115-1123.
25. Lehnert T, Herfarth C. Chemoembolization for hepatocellular carcinoma: what, when, and for whom? Ann Surg. 1996;224:1-3.
26. Harada T, Matsuo K, Inoue T, et al. Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg. 1996;224:4-9.
27. 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology. 1997;26:1156-1161.
28. Rose AT, Rose DM, Pinson CW, et al. Hepatocellular carcinoma outcomes based on indicated treatment strategy. Am Surg. 1998;64:1128-1135.